Detroit R&D, Inc.

Environmental health-, hypertension- and cancer-related research, including biologically active eicosanoids such as EETs and DHETs, prostaglandin H synthases (PGHSs, also called cyclooxygenases, COXs), cytochromes P450 (CYPs), glutathione S-transferases (GSTs), oxidative stress, DNA damage, Xenopus microarray and wound healing

Detroit R&D, Inc. was founded in 1997 by Dr. Hyesook Kim. The company has received funding for five active or completed National Institutes of Health (NIH) SBIR Phase I and II projects (two of these are active Phase II), including hypertension diagnosis, PGHS-dependent DNA damage and microarray projects. Detroit R&D is an awardee of the first round Michigan Life Sciences Corridor Fund as a partner company for elucidation of the mechanisms of a eukaryotic drug pump.

Hyesook Kim (Director of Research, President)

2727 Second Ave., Suite 4113
Detroit, MI 48201
USA
Phone: +1-313+961-1606
Fax: +1-313-963-7130